Fractyl Health to Present at Piper Sandler's 2nd Virtual Obesity Day

Fractyl Health, Inc., a company focusing on innovative treatments for obesity and type 2 diabetes (T2D), announced that its CEO, Dr. Harith Rajagopalan, and CSO, Dr. Timothy Kieffer, will be participating in a virtual fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Day on June 26, 2024. During this event, the company will discuss several significant updates, including the acceleration of its weight maintenance clinical study and recent preclinical findings related to its GLP-1 pancreatic gene therapy platform, Rejuva. Notably, Rejuva demonstrated superior and more lasting weight loss compared to semaglutide in preclinical tests. This finding was presented at the American Diabetes Association’s 84th Scientific Session, where it was selected as the top abstract among 8,000 submissions.

Fractyl Health, headquartered in Burlington, Massachusetts, is dedicated to transforming the treatment of metabolic diseases, particularly obesity and T2D, by developing therapies that target the root causes of these conditions rather than just managing the symptoms. The company’s mission is to shift the paradigm in metabolic disease treatment from chronic symptom management to more enduring, disease-altering therapies.

One of Fractyl Health's leading product candidates is Revita®. This product is based on the company's understanding of the gut's role in obesity and T2D. Revita aims to remodel the duodenal lining through hydrothermal ablation, a process known as duodenal mucosal resurfacing. This method seeks to modify abnormal nutrient sensing and signaling mechanisms in the intestine, which are believed to be fundamental contributors to metabolic diseases. Revita has already received a CE mark in Europe and reimbursement authorization in Germany for treating T2D. In the US, Revita remains investigational and is currently undergoing pivotal studies, including REVITALIZE-1, which targets patients with T2D inadequately controlled on glucose-lowering agents, and the upcoming REMAIN-1, which will focus on patients with obesity who have discontinued GLP-1 based drugs.

Additionally, Fractyl Health is developing the Rejuva® platform, which is in the preclinical stage. This platform focuses on next-generation adeno-associated virus (AAV)-based gene therapies that are delivered locally to treat obesity and T2D. By using advanced delivery systems and proprietary screening methods, Rejuva aims to identify and develop gene therapy candidates that are metabolically active and target the pancreas. The goal of the Rejuva program is to provide novel, disease-modifying therapies that address the core causes of metabolic diseases, offering a potential transformation in how these conditions are managed.

Fractyl Health's commitment to advancing the treatment of metabolic diseases through innovative approaches is underscored by its ongoing research and development efforts. The company is steadfast in its goal to develop therapies that provide long-term control over obesity and T2D, alleviating the burden of chronic therapies for patients. Through its significant advancements in clinical and preclinical research, Fractyl Health continues to pave the way toward groundbreaking treatments that have the potential to significantly improve patient outcomes in metabolic health.